{
  "symbol": "QURE",
  "company": "uniQure N.V.",
  "generated_at": "2026-06-24T07:36:51.906Z",
  "event_count": 3,
  "events": [
    {
      "type": "pipeline_event",
      "ts": "2026-06-22T13:43:22.553Z",
      "stage": "cooldown",
      "outcome": "skip",
      "reason": "recent scout:no_anomaly 0.6h ago < cooldown 168h, no material change",
      "trigger": "[insider_cluster_universe] 3 Form 4 filings in last 14 days · at least one open-market P/S trade verified",
      "source": "idle_hunter"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-06-22T13:09:13.183Z",
      "summary": "The investigation reveals that the Form 4 cluster triggering this dossier consists exclusively of pre-scheduled Rule 10b5-1 plan sales and RSU withholding tax transactions — zero open-market discretionary insider purchases were detected across all filings reviewed. The sole bullish catalyst (FDA agreeing AMT-130 Phase I/II data can support an accelerated BLA for Huntington's disease) fired on June 17, 2026, producing a ~80% single-day surge from $27 to $48. The stock has since given back some gains and now trades at $46.29 with RSI(14) at 78.8 — extremely overbought entering any post-event positioning window. Options chain data is unreliable (null bid/ask across all strikes, IVs showing erroneous values), eliminating the ability to construct spread-based structures. No genuine edge detected.",
      "verdict": "no_anomaly",
      "confidence": 4,
      "tool_calls": 24,
      "walltime_min": 30,
      "debug_path": "dossiers/2026-06-22-QURE.scout.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-06-12T22:45:38.964Z",
      "summary": "The Form 4 cluster that triggered this investigation is a phantom signal: all recent 'acquisitions' are routine RSU vestings at $0 strike price across five directors and one executive (code A, not open-market P-purchase), with simultaneous small tax-hedging sales. No insider made a discretionary open-market purchase in the past 90 days. The stock nearly halved from its FDA setback low (~March 2026 bottom) but remains deeply uncertain — AMT-130's Phase I/II data is 'currently unlikely' to support a US BLA, forcing the company into a Type B FDA meeting and a UK MAA submission path instead. No material edge found in fundamentals or filings that the market has missed; the regulatory risk is well-known.",
      "verdict": "no_anomaly",
      "confidence": 4,
      "tool_calls": 27,
      "walltime_min": 31,
      "debug_path": "dossiers/2026-06-12-QURE.scout.debug.json"
    }
  ],
  "lessons": [],
  "chart_signal": {
    "ticker": "QURE",
    "call": "HOLD",
    "confidence": 2,
    "score": 4,
    "factors": {
      "above_200dma": "+2",
      "above_50dma": "+1",
      "momentum_strong_up": "+2 (74.1%)",
      "rsi_overbought": "-1 (77.6)",
      "macd_above_signal": "+1",
      "recent_macd_bullish_cross": "+1 (3d ago)",
      "broken_below_high": "-2 (-30.5% from high)"
    },
    "summary": "HOLD (score +4) · 12-1 mom 74.1% · RSI 77.6 · above_both · -30.5% from high",
    "last_close": 49.04,
    "one_month_ago_close": 24.76,
    "twelve_month_ago_close": 14.22,
    "twelve_one_momentum_pct": 74.12,
    "rsi_14": 77.6,
    "ma_stack": "above_both",
    "from_period_high_pct": -30.53,
    "period_high": 70.59,
    "price_targets": {
      "bear": 27.82,
      "fair": 44.27,
      "bull": 92.18,
      "bear_return_pct": -43.3,
      "fair_return_pct": -9.7,
      "bull_return_pct": 88,
      "method": "street_targets ⨯ chart_floors",
      "street": {
        "target_low": 34.293015,
        "target_mean": 58.39678,
        "target_high": 92.18398,
        "analyst_count": 11
      }
    },
    "generated_at": "2026-06-24T07:36:51.903Z"
  }
}